Eli Lilly & Co. vs. Lantern Pharma Inc. Common Stock
Eli Lilly & Co. and Lantern Pharma Inc. Common Stock are evenly matched on the factors we track — the better pick depends on what you're optimizing for.
Size & Scale
| LLY | LTRN | |
|---|---|---|
| Market Cap | $1.11 trillion | $31.83 million |
| Revenue (TTM) | $79.67 billion | — |
| Net Income (TTM) | $26.71 billion | $-18,652,935 |
LLY leads on 3 of 3 size & scale factors.
Valuation
| LLY | LTRN | |
|---|---|---|
| P/E Ratio | 42.14 | — |
| Price / Book | 32.74 | -9.89 |
| Price / Sales | 13.92 | — |
LTRN leads on 1 of 1 valuation factors.
Profitability
| LLY | LTRN | |
|---|---|---|
| Net Margin | 33.53% | — |
| Return on Equity | 78.84% | 579.78% |
LTRN leads on 1 of 1 profitability factors.
Dividend
| LLY | LTRN | |
|---|---|---|
| Dividend Yield | 0.55% | — |
| Payout Ratio | 23.23 | — |
LLY and LTRN split the dividend factors evenly.
Risk & Sentiment
| LLY | LTRN | |
|---|---|---|
| Short Interest | 1.29% | 0.21% |
LTRN leads on 1 of 1 risk & sentiment factors.
Dig deeper: LLY overview, LLY financials, LTRN overview, LTRN financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.